4DMedical Ltd (AU:4DX) has released an update.
4DMedical Ltd reports a significant increase in operating revenue, up by 422% to $3.8m in FY2024, largely due to Software-as-a-Service sales and product revenue growth, despite a comprehensive loss of $36.2m. The acquisition of Imbio Inc. contributed to the revenue stream, with the company anticipating Imbio to be cashflow positive in the coming year. No dividends were paid or declared as the company focuses on commercialization and achieving cost synergies.
For further insights into AU:4DX stock, check out TipRanks’ Stock Analysis page.